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28 Oral Presentations0 (0–2), respectively. The median number of hospital admissions
per patient was 1 (range 0–4). The reasons for acute care/ER visits
and hospital admissions were tabulated below.
Reasons for acute care/ER visits and hospital
admissionsAcute care/ER visits fever (n523), bacteremia (2), dehydration (6),
bronchiolitis (1), hemolysis (1), gastrointestinal
bleeding (1), pseudotumor cerebri (2), bandemia
(1)
Hospital admissions conditioning (n58), fever with no positive
cultures (14), bacteremia (8), dehydration (4),
bronchiolitis (1), hemolysis (1), gastrointestinal
bleeding (1), pseudotumor cerebri (1), bandemia
(1), CMV (1)In 82.5% of hospital admissions (33/40), the clinical course was
non-complex, with the discharge diagnosis the same as the admission
diagnosis. In 17.5% (7/40), the course was complicated by conditions
that developed while patients were in hospital, including bacteremia
(n5 3), sepsis (3), adenovirus (1), respiratory distress (2), gastrointes-
tinal bleeding (3), and organ failure (2). The median length of the
non-complex and complex hospitalizations was 4 days (range 1–38)
and 50 days (9–80), respectively. On any day, the mean probability
that a patient would be an out-patient was 78.6% (CI 77.0–
80.1%); the probability that the patient would be an in-patient for
a non-complex or complex stay was 8.8% and 12.6%, respectively
(CI 7.3–10.8% and 11.6–13.6%). In an earlier cohort, in which the
busulfan AUC target was 4000–4600 microM-min (n 5 17), 4 pa-
tients had primary graft failure and 3 died from related complica-
tions. In a later cohort with an AUC target of 5000 (n 5 9), no
patients had primary graft failure or death. Survival in these 2 cohorts
was 81.2 and 100%, respectively (median follow-up 32.2 and 10.5
months). All engrafted patients have stable donor chimerism, im-
proved lymphocyte counts, normalized immune function and de-
creased susceptibility to infection. Our data showed that
ambulatory HSCT utilizing a RIC regimen was highly effective in
children with PID.67
IMPACT OF REDUCED INTENSITY CONDITIONING (RIC) IN PEDIATRIC
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A REPORT FROM THE CIBMTR
Verneris, M.R., Burke, M.J., He, W., Davies, S.M., Eapen, M.,
Wagner, J.E. CIBMTR, Milwaukee, WI
Significant experience now exists with reduced intensity condi-
tion (RIC) regimens prior to allogeneic hematopoietic cell trans-
plantation (HCT) in adults with acute myeloid leukemia and
non-ALL, lymphoid malignancies. Due to concerns that ALL
may require more intensive therapy, there are few reports on the
use of RIC, particularly in children with ALL. Therefore, we eval-
uated the transplant outcomes after RIC and allogeneic HCT in 41
children with ALL. In this retrospective analysis, all patients were
aged 0–18 years with 64% aged 11–18 years; 44% had a Karnofsky
score of\90%; and the disease status at the time of transplant was:
1st complete remission (CR) in 13%, 2nd CR in 41%, and .2nd CR
in 26% and 21% had active disease. The time from diagnosis to
transplant for 1st CR patients was 9 months (8–62 months) and
for $2nd CR patients it was 32 months after 1st CR (range, 6–89
months). 63% were transplanted after 2000. A TBI-based condi-
tioning regimen was used in 33% of patients, while the remainder
(66%) received non-TBI containing regimens consisting of: busul-
fan (34%), cyclophosphamide (15%) and melphalan (17%).
Matched related donors, were available for 37% (50% BM and
50% PBSC), with the remaining (63%) having unrelated donors
(BM in 19%, PBSC in 55% and cord blood in 23%). Most had
GVHD prophylaxis with a calcineurin inhibitor in combination
with either methotrexate (47%) or other agents (41%). The disease
free survival (DFS) and overall survival (OS) at 3 yrs was 31% (95%CI, 16–47%) and 38% (95% CI, 22–54%), respectively. Transplant
related mortality (TRM) at 100 days and 3 years was 18% (95%
confidence interval (CI, 7–30%) and 30% (95% CI, 16–46%).
The incidence of aGVHD (Grade II-IV) at day 1100 was 35%.
At 3 years, cGHVD developed in 23% of patients. Relapse at 3
years was 39% (95% CI, 23–57). This is the largest series describ-
ing outcomes in pediatric patients with ALL undergoing allogeneic
HCT after a RIC. While additional analyses are required, these
data demonstrate that long term DFS and OS can be achieved using
RIC regimens in pediatric patients with ALL.SOLID TUMORS
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ADOPTIVE TRANSFER OF HER2-SPECIFIC T CELLS ERADICATES EXPERI-
MENTAL GLIOBLASTOMA MULTIFORME
Salsman, V.S.1, Kew, Y.2, Powell, S.Z.2, Wels, W.E.3, Grossman, R.2,
Heslop, H.E.1,2, Gottschalk, S.1, Ahmed, N.1 1Baylor College of Medicine,
Houston, TX; 2Weil-Cornell Medical College, Houston, TX; 3Georg-
Speyer-Haus, Frankfurt Am Main, Germany
Background: The intent of this project is to develop an effective
adoptive immunotherapy for glioblastoma multiforme (GBM),
which remains largely incurable with current treatment disciplines.
New therapies are thus needed to improve current outcomes with-
out increasing treatment-related morbidities. Immunotherapies
have the potential to fulfill this need, since they are highly tumor-
specific and cause minimal bystander cell damage. We propose to
use T cells to target the human epidermal growth factor receptor
2 (HER2), a surface antigen, which is overexpressed in GBM.
While the use of HER2 monoclonal antibodies has been limited
by low levels of HER2 expression on GBMs, we show here that
T cells expressing HER2-specific chimeric antigen receptors
(CAR) have potent anti-tumor activity both ex vivo and in animal
models.
Methods: T cells from GBM patients were retroviraly transduced
to express HER2-specific CAR with a CD28.z signaling domain
(HER2-specific T cells). Primary GBM cells and GBM cell lines
were used to test the function of the generated HER2-specific T
cells. The ex vivo efficacy was determined by their ability 1) to kill
HER2-positive target cells in a cytoxicity assay and 2) to proliferate
and secrete cytokines (IFN-g and IL-2) in response to stimulation
with HER2-positive tumor cells. The in vivo efficacy of the
HER2-specific T cells was tested for the ability to induce tumor re-
gression in an orthotopic murine xenograft model.
Results: Primary HER2-specific T cells killed both HER2-pos-
itive autologous GBM cells and GBM cell lines in cytotoxicity
assays, whereas HER2-negative targets were not killed. Stimulation
of HER2-specific T cells with HER2-positive primary GBM cells
and GBM cell lines resulted in T-cell proliferation and secretion
of IFN-g and IL-2 in a HER2-dependent manner. Intra-tumoral in-
jection of HER2-specific T cells resulted in eradication of estab-
lished GBM xenografts in an orthotopic murine model. In
contrast, delivery of non-transduced T cells did not change the
tumor growth pattern.
Conclusion: We demonstrate that T-cells expressing HER2-
specific CARs can recognize and kill HER2-positive GBMs. Their
activation results in proliferation and secretion of immunostiumla-
tory cytokines. HER2-specific T cells can effectively eradicate
established GBM xenografts in an orthotopic murine model. These
results indicate that HER2-specific T cells could represent a promis-
ing immunotherapeutic approach for GBM.STEM CELL BIOLOGY
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IDENTIFICATION AND ISOLATION OF THE HEMATOPOIETIC STEM CELL
NICHE INITIATING CELL POPULATION
Kraft, D., Chan, C., Chen, C.-C., Luppen, C., Weissman, I.L. Stanford
University School of Medicine, Stanford, CA
Introduction: Identification and understanding of the cells and
processes that can generate, sustain and influence the HSC niche and
Oral Presentations 29hematopoiesis are critical for the development of a more comprehen-
sive knowledge of normal hematopoiesis, stem cell homing, trafficking,
differentiation and hematopoietic pathology. Growth and renewal in
many tissues are initiated by stem cells, supported by the microenvi-
ronment (niche) in which they reside. While recent work has begun
to describe functional interactions between stem cells and their niches,
little is known about the formation of stem cell niches.
Methods & Results: We established a functional, in vivo assay
(via implantation of cells under the renal capsule) to isolate
the determinants of hematopoietic stem cell (HSC) niche
formation and activity. Using this novel assay, we show that a pop-
ulation of progenitor cells (CD45-Tie2-aV1CD1051Thy1.1-;
CD1051Thy1-) sorted from 15.5 dpc fetal limbs and transplanted
under the adult mouse renal capsule recruit host-derived vascula-
tures in a VEGF dependent manner, produce donor-derived
ectopic bones through endochondral ossification, and generate
a marrow cavity populated by host-derived long term reconsti-
tuting HSC (LT-HSC). In contrast, CD45-Tie2-aV1
CD1051Thy1a1 (CD1051Thy11) progenitors form bone that
does not contain a marrow cavity. While analyzing these and other
sorted populations, we did not observe any instances where niche
was present without bone, suggesting that skeletal progenitors
are necessary for initiating an HSC niche but osteoblasts alone
cannot initiate and support niche activity. Suppression of factors
important for HSC maintenance, such as steel factor (SLF),
in progenitor populations prior to transplant did not alter their
ability to initiate and support an HSC niche. On the other hand,
suppression of factors involved in endochondral ossification, such
as osterix and VEGF, inhibited niche generation. Furthermore,
CD1051Thy1- progenitor populations derived from regions of
the fetal mandible or calvaria that do not undergo endochondral
ossification form only bone without marrow in our assay.
Conclusions: In addition to identifying the limb-derived skeletal
progenitor capable of endochondral ossification involved and the
basic mechanisms of HSC niche initiation, our study provides a func-
tional framework by which future studies on HSC-niche interactions
at the cellular level can be carried out.70
DEPLETION OF CD31 AND/OR CD141 CELLS FROM CORD BLOOD IM-
PROVES EX VIVO EXPANSION
Yang, H.1, Robinson, S.N.1, Decker, W.K.1, Xing, D.1, Steiner, D.1, Lu ,
de Lima M.J., J.1,1, Champlin, R.E.1, Simmons, P.J.2, Shpall, E.J.1
1University of Texas M.D. Anderson Cancer Center, Houston, TX; 2Uni-
versity of Texas Health Science Center at Houston, Houston, TX
Cord blood (CB) is a viable alternative to bone marrow (BM) or
mobilized peripheral blood (mPB) for transplantation. While CB is
collected, typed, frozen and banked as a readily available source of
ethnically-diverse tissue for transplant, a major limitation of CB
transplantation is low cell dose leading to delayed engraftment
and increased risk of engraftment failure. Ex vivo expansion of
CB could improve transplant outcomes by increasing cell dose. Us-
ing a mesenchymal stem cell (MSC) co-culture system, significant
levels of CD341 cell expansion can be achieved. However, the pres-
ence of non-CD341 accessory cells may impact the efficiency of
expansion. Thawed CB units contain (mean 6 SEM, n 5 114)
1.4 6 0.6% CD341, 39.5 6 1.2% CD31, 17.1 6 0.7% CD191,
15.3 6 0.7% CD141 and 20.1 6 1.2% CD561 cells. Preliminary
experiments demonstrated that only CD31 and/or CD141 in-
hibited CD341 expansion. No positive or negative impact was ob-
served for any other cell population. These data suggested CD31
and CD141 cells as candidate populations for investigation. Our
hypothesis is that the depletion of CD31 and/or CD141 cells
from CB MNC will markedly improve CD341 expansion in the
MSC co-culture system.
Methods: CD31 and/or CD141 cells were removed from a single
CB unit by magnetic depletion (MACS, Miltenyi) and the products
cultured in the MSC co-culture system. Comparisons were made be-
tween the CD341 and total nucleated cell (TNC) expansion
achieved in the MSC co-culture system following the incubation of
MNC (nothing depleted), MNC depleted of CD31 cells (MNC-
CD31), CB MNC depleted of CD141 cells (MNC-CD141) and
CB MNC depleted of both CD31 and CD141 cells (MNC-
(CD31 1 CD141)). Incubations were performed in mediumcontaining Flt-3L, SCF, G-CSF and TPO for 7 days. On day 7,
non-adherent (n/a) cells were removed and cultured in liquid culture
conditions (no MSC) for a further 7 days. On Day 14, n/a cells from
the co-culture flask and liquid cultures were pooled and evaluated for
TNC and CD341 cell content.
Results:
Fold increase over input (range: min-max, n53)
TNC CD341MNC 3.5-19.8 11.3-12.4
MNC-CD31 21.2-47.4 19.2-51.3
MNC-CD141 8.3-27.0 23.6-32.4
MNC-(CD31 1 CD141) 27.8-41.0 23.9-55.1Conclusion: The depletion of CD31 and/or CD141 cells from
the CB MNC increased ex vivo expansion of TNC and CD341
when compared with original CB MNC expansion. GMP-compliant
antibodies that target CD3 and CD14 are available (Miltenyi) and
could be used for clinical evaluation of this strategy.SUPPORTIVE CARE
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NEW MOBILIZATION STRATEGIES FOR COLLECTION OF PERIPHERAL
BLOOD PROGENITOR CELLS FOR LYMPHOMA AND MYELOMA PATIENTS
Smith, V.R., Hosing, C., Popat, U., Schindler, J. University of Texas MD
Anderson Cancer Center, Houston, TX
Autologus stem cell transplantation (SCT) is a common treat-
ment modality for lymphoma and myeloma patients. The success
of SCT depends on the collection of adequate number of CD34
positive cells. Standard mobilization therapy consits of granulo-
cyte-colony-stimulating factor G-CSF and Sargramostine (GM-
CSF). Some patients that are mobilized with G-CSF alone fail to
collect the target cell dose while others are able to collect target
dose after numerous apheresis procedures. In Autologus progenitor
cell moblizaton, the addition of chemotherapy in conjunction with
G-CSF/GM-CSF can substantially increase the yield of CD34
peripheral blood progenitor stem cells (PBSC), it is not without
significant toxicities, additional cost and quality of life issues.
Inadequate stem cell mobilization is seen in approximtely 25% of
patients undergoing autotransplantation for hematologic malig-
nancies. Experience has shown that patients who fail initial mobili-
zation are likely to fail remobilization. Alternative strategies are
needed for donors who fail to mobilize adequate number of stem
cells with standard therapy. Plerixafor (AMD 3100) is a new and
promising agent being studied for use in mobilization of preipheral
blood progenitor cells in patients with lymphoma and myeloma.
AMD 3100 is a bicyclam derivate that specifically and reversibly in-
hibits binding of SDF-1 to its receptor CXCR4 leading to stem cell
mobilization. Plerixafor can be used alone or in conjunction with
G-CSF for stem cell mobilization. Two phase III, multicenter, ran-
domized, double-blinded, placebo-controlled studies compared
AMD3100 plus G-CSF with G-CSF alone for mobilization of
stem cells in patients with myeloma and NHL. Patients recieved
G-CSF at 10ug/kg/day subcutaneoulsy for 4 days and on the even-
ing of the fourth day they recieved either AMD3100 at 240 ug/kg
subcutaneously or placebo. The aphereses started on day five, after
the morning dose of G-CSF, and continued until CD341was#5
106/kg (NHL) or #6  106/kg (MM) or total of four collections.
Patients continued recieving their morning doses of G-CSF and
evening dose of study drug until collection was complete. Patients
who falied to collect#2 106CD341 cells/kg were eligible for res-
cue with AMD3100 plus G-CSF. These studies confirmed that the
addition of AMD3100 to G-CSF is safe and well tolerated. Patients
mobilized with AMD3100 plus G-CSF were more likely to achieve
a target CD341 cell count with less apheresis and had successful
transplant.
